FF301 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 600332 | 說明 | | 於上海證券交易所 （「上交所」）上市之A股 | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,405,890,949 | RMB | | 1 RMB | | 1,405,890,949 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 1,405,890,949 | RMB | | 1 RMB | | 1,405,890,949 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 （「本公司」） 呈交日期: 2025年8月1日 I ...

廣州白雲山醫藥集團股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 董事會 董事會會議召開日期 廣州白雲山醫藥集團股份有限公司（「本公司」）董事會（「董事會」）茲通告謹定於2025年8月15日（星期 五）舉行董事會會議，藉以審議及批准本公司及其附屬公司截至2025年6月30日止六個月未經審計財 務業績及處理其他事項（如有）。 中國廣州，2025年8月1日 於本公告日，本公司董事會成員包括執行董事李小軍先生、程寧女士、程洪進先生、唐和平先生與 黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 ...

格隆汇8月1日丨白云山(00874.HK)公布，谨定于2025年8月15日(星期五)举行董事会会议，藉以审议及 批准公司及其附属公司截至2025年6月30日止六个月未经审计财务业绩及处理其他事项(如有)。 ...

中國廣州，2025年8月1日 於本公告日，本公司董事會成員包括執行董事李小軍先生、程寧女士、程洪進先生、唐和平先生與 黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 廣州白雲山醫藥集團股份有限公司（「本公司」）董事會（「董事會」）茲通告謹定於2025年8月15日（星期 五）舉行董事會會議，藉以審議及批准本公司及其附屬公司截至2025年6月30日止六個月未經審計財 務業績及處理其他事項（如有）。 廣州白雲山醫藥集團股份有限公司 董事會 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 董事會會議召開日期 ...

FF301 致：香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 （「本公司」） 呈交日期: 2025年8月1日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 I. 法定/註冊股本變動 1. 股份分類 普通股 股份類別 H 於香港聯交所上市 (註1) 是 證券代號 (如上市) 00874 說明 香港聯交所上市 H 股 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 219,900,000 RMB 1 RMB 219,900,000 增加 / 減少 (-) RMB 本月底結存 219,900,000 RMB 1 RMB 219,900,000 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 600332 | 說明 | | 於上海證券交易所 （「上交所」）上市之A股 | | | | | | | | 法定/ ...

Key Points - The top three companies with net inflows from southbound funds are Xiaomi Group-W (01810) with 1.665 billion, Tencent Holdings (00700) with 830 million, and Alibaba-W (09988) with 747 million [1] - The companies with the highest net outflows are Pop Mart (09992) with -354 million, China Life (02628) with -351 million, and Kingsoft Cloud (03896) with -300 million [1] - In terms of net inflow ratio, Qin Port Co. (03369) leads with 78.68%, followed by Reshaping Energy (02570) with 76.94%, and Cang Port Railway (02169) with 65.01% [1] - The companies with the highest net outflow ratios include Chongqing Rural Commercial Bank (03618) at -61.37%, Bank of China Aviation Leasing (02588) at -53.31%, and Swire Properties (01972) at -45.99% [1] Net Inflow Rankings - Xiaomi Group-W (01810) had a net inflow of 1.665 billion, representing a 12.37% increase [2] - Tencent Holdings (00700) saw a net inflow of 830 million, with an 8.94% increase [2] - Alibaba-W (09988) recorded a net inflow of 747 million, reflecting a 10.60% increase [2] - The highest net inflow was observed in CSPC Pharmaceutical Group (01093) with 654 million and a 21.81% increase [2] Net Outflow Rankings - Pop Mart (09992) experienced a net outflow of -354 million, with a -10.47% decrease [2] - China Life (02628) had a net outflow of -351 million, reflecting a -11.90% decrease [2] - Kingsoft Cloud (03896) recorded a net outflow of -300 million, with a -24.18% decrease [2] - Meituan-W (03690) also saw a significant outflow of -291 million, representing a -5.32% decrease [2] Net Inflow Ratio Rankings - Qin Port Co. (03369) leads with a net inflow ratio of 78.68% and a net inflow of 340,000 [3] - Reshaping Energy (02570) follows with a net inflow ratio of 76.94% and a net inflow of 10.53 million [3] - Cang Port Railway (02169) has a net inflow ratio of 65.01% with a net inflow of 4.3967 million [3] - Other notable companies include Meizhong Jiahe (02453) with a 61.71% net inflow ratio [3] Net Outflow Ratio Rankings - Chongqing Rural Commercial Bank (03618) has the highest net outflow ratio at -61.37% with a net outflow of -1.04 billion [3] - Bank of China Aviation Leasing (02588) follows with a net outflow ratio of -53.31% and a net outflow of -15.3728 million [3] - Swire Properties (01972) has a net outflow ratio of -45.99% with a net outflow of -29.4662 million [3]

Core Insights - The Chinese life sciences industry is undergoing rapid transformation driven by policy relaxation, technological innovation, the rise of domestic companies, and the development of specialized real estate ecosystems [9][18][39] - The report "Trends in China's Life Sciences" provides a comprehensive overview of current market dynamics, regulatory changes, and future development directions [9] Policy Environment - Nationally, China has relaxed foreign investment restrictions in gene and cell therapy, allowing foreign-owned hospitals in major cities [10][20] - Local governments in cities like Beijing, Shanghai, and Shenzhen are offering targeted subsidies and fast-track approval processes to support biotechnology development [10][27] Industry Innovation and Company Growth - Chinese life sciences companies are shifting from generic drug production to innovative therapies, with firms like CanSino Biologics and BeiGene leading in CAR-T cell therapy and bispecific antibodies [11][29] - These companies are attracting international investment and licensing agreements, enhancing China's position in the global life sciences sector [11][39] Real Estate Development and Regional Hubs - Innovation hubs such as Suzhou BioBay and Shanghai Zhangjiang Hi-Tech Park provide end-to-end support, including shared laboratories and GMP-compliant facilities [12][35] - Second-tier cities like Chengdu and Ningbo are emerging as new growth centers, expanding the life sciences ecosystem [12][35] Owner Perspective - Real estate developers are adapting to industry-specific needs through light-asset models and flexible leasing arrangements [14][45] - While first-tier cities face saturation, demand remains robust in central and western regions, with a focus on sustainability and compliance [14][45] Tenant Perspective - Life sciences tenants are responding to regulatory reforms and increased compliance requirements, seeking flexibility and proximity to talent and infrastructure [15][46] - The highest demand is for GMP-certified laboratories and modular production facilities, emphasizing location advantages and sustainability certifications [15][46] Future Outlook - Growth opportunities lie in AI-driven drug development, personalized medicine, and advanced therapies, supported by government policies [16][39] - Life sciences real estate is evolving from generic parks to specialized, digitally-enabled facilities with high compliance and flexibility [16][39]

Group 1 - The 2025 Fortune Global 500 list reveals that the total revenue of the listed companies is approximately $41.7 trillion, which exceeds one-third of the global GDP, marking a growth of about 1.8% compared to the previous year [1] - A total of 130 Chinese companies made the list, ranking second after the United States, with a combined revenue of approximately $10.7 trillion for 2024 [1] - High-tech sectors are highlighted as the forefront of global technological development, with significant performance improvements among listed high-tech companies [1] Group 2 - Guangzhou Pharmaceutical Holdings is the only Chinese company included in the pharmaceutical sector of the 2025 Fortune Global 500 list, having been listed for three consecutive years [2] - The pharmaceutical sector features eight American companies and seven European companies, while China has three companies listed [5] Group 3 - Chinese pharmaceutical companies, including Guangzhou Pharmaceutical, have made significant advancements in research and development, with over 200 ongoing projects in various drug categories [6] - The Chinese pharmaceutical industry is transitioning towards innovative drugs and biopharmaceuticals, with leading companies driving this transformation through independent research and strategic mergers [8] Group 4 - Digital transformation is essential for Chinese pharmaceutical companies, with initiatives underway to enhance competitiveness and quality management across the entire industry chain by 2027 [9] - Guangzhou Pharmaceutical is implementing a comprehensive digital strategy, including smart production and logistics systems, and has partnered with Huawei for digital transformation [9] Group 5 - The internationalization of traditional Chinese medicine is accelerating, with Chinese companies expanding their global presence through product development and market outreach [11] - Guangzhou Pharmaceutical's products have reached over 29 countries and regions, and the company is actively pursuing strategic partnerships to enhance its international footprint [11] Group 6 - Capital operations are becoming a powerful lever for resource integration and industry upgrades in the pharmaceutical sector [13] - Guangzhou Pharmaceutical is transitioning to a modern model of "industry incubation + capital operation," with recent acquisitions and the establishment of investment funds to support growth in the biopharmaceutical sector [14] Group 7 - The Fortune Global 500 list serves as a motivational signal for Chinese companies, indicating the rising position of Chinese innovative drugs in the global pharmaceutical industry [15] - The Chinese pharmaceutical sector is experiencing unprecedented vitality, marking the beginning of a new era in pharmaceutical innovation [15]

证券之星 刘凤茹 证券之星注意到，白云山营收降幅较大的产品是阿莫西林系列，该产品2024年的营收同比下滑36.65%，对应营收为1.79亿元。内科用药方面，消渴丸2024年实现营收4.01亿元，同比下降23 大健康板块作为利润来源的第二大业务，主要为饮料、食品、保健品等产品的生产、研发与销售。大健康板块收入主要来自王老吉凉茶。对王老吉凉茶的销售，王老吉大健康公司及王老吉药业主 2024年，大健康板块实现营收97.05亿元，同比下降12.7%，该业务毛利率为43.12%，同比减少1.29个百分点。去年，王老吉大健康公司实现营收87.64亿元，同比下降12.47%；净利润11 证券之星注意到，白云山的大健康板块也一直在推出新品。白云山表示，刺柠吉、荔小吉作为公司的新品，尚在培育期。公司刺柠吉、荔小吉、核桃露、椰汁等产品将根据不同市场与渠道需求 股权投资"黑天鹅"，3.86亿减值吞利润 主业之外，白云山还提到，报告期内，根据《企业会计准则》的相关规定，公司对一心堂长期股权投资计提资产减值准备3.86 亿元。对一心堂的长期股权投资成为业绩"黑天鹅"。 回溯历史，2017年1月，白云山官宣拟以8亿元自有资金认购一心堂非 ...

Core Viewpoint - Baiyunshan (00874) has entered into a partnership agreement with Guangyao Capital to establish the second phase of the Guangyao Fund, aiming to enhance its investment in the biopharmaceutical sector and accelerate its strategic development in the healthcare industry [1]. Group 1: Company Actions - Baiyunshan's stock price increased by 2.65%, reaching HKD 18.60, with a trading volume of HKD 69.445 million [1]. - The company will invest RMB 1.4985 billion and Guangyao Capital will contribute RMB 1.5 million to the Guangyao Fund II [1]. - The financial performance of Guangyao Fund II will be consolidated into Baiyunshan's financial statements [1]. Group 2: Investment Focus - The partnership aims to conduct equity investments in the biopharmaceutical field, targeting investment returns [1]. - The fund will focus on investments in pharmaceuticals, medical devices, and healthcare services, aligning with the company's strategic planning [1]. - The establishment of Guangyao Fund II is intended to seize industry development opportunities and enhance the company's investment efforts in the biopharmaceutical and health sectors [1].